By: Connor Iapoce
Brolucizumab achieved non-inferiority in mean BCVA change to aflibercept in eyes with nAMD but demonstrated a higher incidence of IOI at 2 years.
Connor Iapoce is an Associate Editor for various publications including HCP Live, Cliggott Publishing Co, and Contemporary Pediatrics. With a focus on healthcare and medical topics, Connor's articles cover a wide range of subjects including clinical trials, treatment advancements, and the impact of various medical conditions on patient outcomes. His work has also been featured in AJMC - The American Journal of Managed Care and Drug Topics.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Connor's coverage predominantly focuses on scientific and healthcare topics, particularly in ophthalmology, medical research, and drug importation. His articles are heavily reliant on cited data to support the information presented.
For effective outreach to Connor, consider providing access to reliable and up-to-date scientific data or studies related to ophthalmology, medical research, or drug importation. Experts who can provide valuable insights supported by credible data would likely be well-received by him.
Given the technical nature of his coverage areas, sources with a strong background in these fields may have an advantage in reaching out effectively.
This information evolves through artificial intelligence and human feedback. Improve this profile .